N/A N=25 Trimodal Prehabilitation for Aneurysm Surgery Study
Aortic Aneurysm
Primary: The Number of Patients Who Accepted Inclusion Into a Pre-operative Prehabilitation Programme — 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Trial of Quetiapine in Anorexia Nervosa
Anorexia Nervosa
Primary: Hours Occupied by Preoccupations and Rituals Assessed by Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) — NA; NA; NA; NA Hours — p=.15
N/A N=302 ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
Obesity
Primary: Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group — 9.5; 2.8 % Total Body Weight Loss — p=<0.0001
N/A N=5 Sustaining Physical Activity Following Cardiac Rehabilitation Completion
Cardiac Rehabilitation
Primary: Average Steps Per Day (Preintervention Period) — 6507 steps per day
Phase 4 N=79 Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy
Posterior Capsule Opacification · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at 1 Hour After Nd-YAG Posterior Capsulotomy — 15.6; 15.7; 15.2; 13.7 mmHg — p=<0.05
N/A N=33 Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy
Diabetic Foot Ulcers
Primary: Ease of Use Assessment — 0; 3; 14; 13 Participants
N/A N=30 What is the Optimal Stiffness and Height of a Running-specific Prosthesis?
Amputation, Traumatic · Traumatic Amputation of Lower Extremity · Wounds and Injuries
Primary: Biomechanics — 0.1386; 0.1835 N/kg
N/A N=21,726 Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations
HIV Infection
Primary: Proportion Reporting HIV Testing in the Prior 12 Months — 36.9; 26.2 percentage of participants — p=0.09
Phase 1 N=40 Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin — 5033.8718; 6142.2821; 6090.7932 nanogram*hour per…
Phase 2 N=66 Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Cystic Fibrosis
Primary: Clinically Significant Laboratory Abnormalities. — 1; 0; 8; 7 Participants
Phase 2 N=161 A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
Chronic Hepatitis C
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) — 17; 19; 14; 13 Participants
Phase 2 N=23 Cryoanesthesia for Intravitreal Injections
Ocular Anesthesia
Primary: Subjective Injection Pain — 7.0; 3.1; 3.0; 1.8 units on a scale
N/A N=68 Rwanda Vaginal Microbiota Restoration Study
Bacterial Vaginosis
Primary: Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria — 7.53; 2.04; 3.36; 3.35 Incidence: events per PY at risk
N/A N=1,520 HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
Age Related Macular Degeneration
Primary: Primary Outcome: Change in Visual Acuity (LogMAR Letters) From Baseline to Detection of Choroidal Neovascularization — -7.4; -12.6 LogMAR letters (ETDRS)
Phase 2 N=10 University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial
Autism Spectrum Disorders
Primary: Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2) — -1.6; -0.4 units on a scale — p=0.0028